Switch theme
Sign up to access all valuation multiples
Acrobiosystems Co Ltd is a global brand focusing on protein technology, products and services in the development of biological drugs. It is committed to providing target antigens and other key reagents and related services required in the development of targeted therapeutic drugs.
2010
n/a
LTM Revenue $102M
LTM EBITDA $24.5M
$964M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ACROBiosystems has a last 12-month revenue (LTM) of $102M and a last 12-month EBITDA of $24.5M.
In the most recent fiscal year, ACROBiosystems achieved revenue of $90.0M and an EBITDA of $25.4M.
ACROBiosystems expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ACROBiosystems valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $102M | XXX | $90.0M | XXX | XXX | XXX |
| Gross Profit | $92.5M | XXX | $81.9M | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | $24.5M | XXX | $25.4M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $19.7M | XXX | $15.3M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $20.1M | XXX | $17.3M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, ACROBiosystems's stock price is CNY 51 (or $7).
ACROBiosystems has current market cap of CNY 8.6B (or $1.2B), and EV of CNY 6.9B (or $964M).
See ACROBiosystems trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $964M | $1.2B | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, ACROBiosystems has market cap of $1.2B and EV of $964M.
ACROBiosystems's trades at 10.7x EV/Revenue multiple, and 38.0x EV/EBITDA.
Equity research analysts estimate ACROBiosystems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ACROBiosystems has a P/E ratio of 59.8x.
See valuation multiples for ACROBiosystems and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $964M | XXX | $964M | XXX | XXX | XXX |
| EV/Revenue | 9.5x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBITDA | 39.4x | XXX | 38.0x | XXX | XXX | XXX |
| EV/EBIT | 48.9x | XXX | 63.2x | XXX | XXX | XXX |
| EV/Gross Profit | 10.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 59.8x | XXX | 69.6x | XXX | XXX | XXX |
| EV/FCF | 187.8x | XXX | -83.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialACROBiosystems's last 12 month revenue growth is 24%
ACROBiosystems's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
ACROBiosystems's rule of 40 is 62% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ACROBiosystems's rule of X is 83% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ACROBiosystems and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 36% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | 62% | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 83% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ACROBiosystems acquired XXX companies to date.
Last acquisition by ACROBiosystems was XXXXXXXX, XXXXX XXXXX XXXXXX . ACROBiosystems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ACROBiosystems founded? | ACROBiosystems was founded in 2010. |
| Where is ACROBiosystems headquartered? | ACROBiosystems is headquartered in China. |
| Is ACROBiosystems publicy listed? | Yes, ACROBiosystems is a public company listed on SHE. |
| What is the stock symbol of ACROBiosystems? | ACROBiosystems trades under 301080 ticker. |
| When did ACROBiosystems go public? | ACROBiosystems went public in 2021. |
| Who are competitors of ACROBiosystems? | Similar companies to ACROBiosystems include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of ACROBiosystems? | ACROBiosystems's current market cap is $1.2B |
| What is the current revenue of ACROBiosystems? | ACROBiosystems's last 12 months revenue is $102M. |
| What is the current revenue growth of ACROBiosystems? | ACROBiosystems revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of ACROBiosystems? | Current revenue multiple of ACROBiosystems is 9.5x. |
| Is ACROBiosystems profitable? | Yes, ACROBiosystems is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ACROBiosystems? | ACROBiosystems's last 12 months EBITDA is $24.5M. |
| What is ACROBiosystems's EBITDA margin? | ACROBiosystems's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of ACROBiosystems? | Current EBITDA multiple of ACROBiosystems is 39.4x. |
| What is the current FCF of ACROBiosystems? | ACROBiosystems's last 12 months FCF is $5.1M. |
| What is ACROBiosystems's FCF margin? | ACROBiosystems's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of ACROBiosystems? | Current FCF multiple of ACROBiosystems is 187.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
